T1	Premise 584 755	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
T3	Premise 797 939	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
T2	Premise 1021 1169	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
T4	Claim 1170 1300	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
T5	Claim 1301 1364	Both drugs were well tolerated with mild ocular adverse events.
T6	Premise 756 796	Adverse events were mild in both groups;
R1	Support Arg1:T6 Arg2:T5	
R2	Partial-Attack Arg1:T3 Arg2:T6	
R3	Support Arg1:T1 Arg2:T4	
R4	Support Arg1:T2 Arg2:T5	
